Article
Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.
American journal of hematology - 1 Sept 2013
Bagratuni Tina, Kastritis Efstathios, Politou Marianna, Roussou Maria, Kostouros Efthimios, Gavriatopoulou Maria, Eleutherakis-Papaiakovou Evangelos, Kanelias Nikolaos, Terpos Evangelos, Dimopoulos Meletios A
Abstract excerpt
Lenalidomide has significant antimyeloma activity but it is associated with a significant risk of venous thromboembolism (VTE). In this study, we assessed clinical and genetic risk factors that may predispose for VTE in myeloma patients who were treated with lenalidomide-based regimens. We analyzed common clinical and selected genetic factors in 200 consecutive, unselected myeloma patients who were treated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.